Design of potent peptide mimetics of brain-derived neurotrophic factor.
about
Deoxygedunin, a natural product with potent neurotrophic activity in mice7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disordersNovel small molecule activators of the Trk family of receptor tyrosine kinasesAmitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activityNeurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's diseaseCyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in miceEthanol-BDNF interactions: still more questions than answers.BDNF-mediated enhancement of inflammation and injury in the aging heart.Cyclic-AMP response element-based signaling assays for characterization of Trk family tyrosine kinases modulators.Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signalsSynthetic constrained peptide selectively binds and antagonizes death receptor 5.A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone.Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists.Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents.Small molecule mimetics of an HIV-1 gp41 fusion intermediate as vaccine leads.Neurogenic and neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell culturesAssociation between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia.Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteersAssembling ligands in situ using bioorthogonal boronate ester synthesisPeptide-mediated targeting of liposomes to TrkB receptor-expressing cells.Intraperitoneal Administration of a Novel TAT-BDNF Peptide Ameliorates Cognitive Impairments via Modulating Multiple Pathways in Two Alzheimer's Rodent Models.Novel therapeutic targets for Huntington's disease.RNA aptamer-based functional ligands of the neurotrophin receptor, TrkBCurrent advances in using neurotrophic factors to treat neurodegenerative disordersEnviromimetics: exploring gene environment interactions to identify therapeutic targets for brain disorders.Role of BDNF in central motor structures and motor diseases.From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF)Neurotrophin strategies for neuroprotection: are they sufficient?Design of a conformationally defined and proteolytically stable circular mimetic of brain-derived neurotrophic factor.Antidepressant Effect of Dimeric Dipeptide GSB-106, an Original Low-Molecular-Weight Mimetic of BDNF.Role of the conformational versatility of the neurotrophin N-terminal regions in their recognition by Trk receptors.Pressuromodulation at the cell membrane as the basis for small molecule hormone and peptide regulation of cellular and nuclear functionOvercoming the inhibitors of myelin with a novel neurotrophin strategy.Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease.A small peptide mimetic of brain-derived neurotrophic factor promotes peripheral myelination.
P2860
Q21136320-0A86946A-49F8-482B-9829-A5B06CF4DA39Q21999335-72A3D272-A9B9-41C5-A6B1-FF50512FE702Q24601637-3718A4BB-15C4-4D4A-9C09-9E33A01221DFQ24615575-F8D0517D-A530-4C8E-A959-6D7515AEE863Q26741247-5A15BD0C-C157-4490-A056-EA6BABC18C18Q28473290-946707A7-56CA-4A0B-B07D-CF238DB63CABQ30490427-3D06E05B-84D9-4478-9902-6382117FB5ECQ33229423-71EB32CD-E69C-4122-9B56-F05446F893DAQ33250001-C5576543-B4B2-45AA-A85E-C09DEDCA8A6DQ33500614-7B3C09B8-D07F-42BD-9B14-3AA204FC82BCQ33531333-A7FDB999-C7DD-4E00-A1CC-5FD9F7608A42Q33664194-07017381-008D-4D00-9004-5071C71343B8Q34010191-8E91463E-F6E6-4D05-9EA1-0A37D64D7E32Q34111160-287E4371-9A7C-49C7-B6AB-DBD9528D0044Q34412591-DDD38870-A4C1-45A0-B95A-BE1819661D87Q34548310-72476641-D6E2-4A4C-9688-45294E585A99Q34706991-BAB048C7-0BE7-4A51-8D0C-9E0FBAEF4516Q34726039-64ECF416-43B6-4F70-AEE3-918F625DFF32Q35146759-2A8CF5F5-A7F8-41B2-AD49-1E28E1DC443EQ36119579-2F494597-6BE5-4017-82C6-0F38801DE1DDQ36158803-EF62DB81-9680-4298-A15E-2761D3B66B3BQ36219680-8580937D-B6A1-493D-9875-72EB71C41C4BQ36294425-418F6ACA-B9FB-4215-AF60-FBB1C873C4CDQ36525034-4CD26943-80E8-4B02-BB14-7E490B3F9727Q36871981-6DFE8EBF-9B15-4881-8976-47330599F02BQ38104654-EF13077F-245F-4D7D-B607-7EABE0B02A59Q38168376-BAF7359E-6C8E-4208-8061-0472A518454BQ38194485-52F199F2-F579-4113-9020-9412C4C24036Q39937019-30453524-AD2E-4F12-8708-37A8B629F122Q41870220-AA643AF1-4585-40AD-BCFE-7F775536FC4DQ41915263-CF9617F8-2F7C-4B02-9265-9B5265C73ED1Q42153567-1E3F636F-1A43-4C44-A12A-7E66EFA2AB40Q42823060-B80CA2C1-8705-4D33-BEEB-DBEB49F2E768Q47280331-B72CE9A3-241E-4C15-9F05-B0BFE6C08DAFQ48194156-A3002474-EEFE-4903-BF39-BCC752385215
P2860
Design of potent peptide mimetics of brain-derived neurotrophic factor.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Design of potent peptide mimetics of brain-derived neurotrophic factor.
@en
Design of potent peptide mimetics of brain-derived neurotrophic factor.
@nl
type
label
Design of potent peptide mimetics of brain-derived neurotrophic factor.
@en
Design of potent peptide mimetics of brain-derived neurotrophic factor.
@nl
prefLabel
Design of potent peptide mimetics of brain-derived neurotrophic factor.
@en
Design of potent peptide mimetics of brain-derived neurotrophic factor.
@nl
P2860
P356
P1476
Design of potent peptide mimetics of brain-derived neurotrophic factor.
@en
P2093
Paul D O'Leary
Richard A Hughes
P2860
P304
25738-25744
P356
10.1074/JBC.M303209200
P407
P577
2003-05-02T00:00:00Z